Host factors determining the efficacy of hepatitis C treatment.
about
Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis.Role of genetic polymorphisms in hepatitis C virus chronic infection.Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan.Association of IL28B SNPs rs12979860 and rs8099917 on Hepatitis C Virus-RNA Status in Donors/Recipients of Living Donor Liver Transplantation.Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma RiskLack of association between interleukin 28B gene polymorphisms (rs8099917G/T, rs12979860 C/T) and susceptibility to chronic hepatitis C virus infection, Tehran, Iran.Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease.Individualization of chronic hepatitis C treatment according to the host characteristics.Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection.Characterisation of the cytokine milieu associated with the up-regulation of IL-6 and suppressor of cytokine 3 in chronic hepatitis C treatment non-responders.Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.SOCS-1 promoter methylation and treatment response in chronic hepatitis C patients receiving pegylated-interferon/ribavirin.
P2860
Q26828972-FD42BAD9-637B-44AD-B331-8444753AE567Q31168457-8C868BC4-A339-464D-819C-D419BBCF144DQ35779058-9127D938-C0E8-4BDF-B12A-23FE674CBA19Q36009124-284B61F5-37F6-448B-AE3E-084C475D7113Q36044806-4F787B32-B3BD-49BD-B061-0995661F35DFQ36316508-412BBB2D-8C4D-49A1-8D20-827E546A1746Q37643650-359C30BD-0F09-40FC-B73E-5AB8DBB57D66Q37646759-1AC24C61-FB0C-4441-9900-CB3E63FC8C30Q37654502-71FBF276-D899-4609-BAD0-DDC3E4FFAEA6Q40167729-19EFE207-8398-497B-A098-7EB92C1FA3F9Q41161023-E3A1B28A-998F-4E95-A07B-273AB8FE9437Q42241367-C074A606-B147-4EB6-8C77-098E3236CF4AQ42694877-1B4FDCD5-F92B-4BBD-A969-718E0F6D5B76Q42992475-3471C9E6-1610-4754-AD1E-5375F5BBEEB8
P2860
Host factors determining the efficacy of hepatitis C treatment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Host factors determining the efficacy of hepatitis C treatment.
@en
type
label
Host factors determining the efficacy of hepatitis C treatment.
@en
prefLabel
Host factors determining the efficacy of hepatitis C treatment.
@en
P2860
P1476
Host factors determining the efficacy of hepatitis C treatment
@en
P2093
Wan-Long Chuang
P2860
P356
10.1007/S00535-012-0669-X
P50
P577
2012-10-27T00:00:00Z